Biofrontera (BFRI) Gains from Investment Securities (2020 - 2026)
Biofrontera (BFRI) posted quarterly Gains from Investment Securities of -$482000.0 for Q4 2025, down 37.32% year-over-year from -$769009.1 in Q4 2024, and down 269.12% quarter-over-quarter from $285000.0 in Q3 2025.
Biofrontera (BFRI) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Biofrontera's Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$482000.0 for Q4 2025.
- In Q4 2025, Gains from Investment Securities fell 37.32% year-over-year to -$482000.0; the TTM figure through Dec 2025 stood at -$898000.0 (up 46.55% YoY), while the FY2025 annual figure was -$899000.0, up 46.49% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$482000.0, down from $285000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $11.1 million in Q4 2021, with the low at -$8.7 million in Q1 2022.
- The 5-year median for Gains from Investment Securities is -$275500.0 (2023), against an average of -$868055.6.
- The sharpest annual moves came in 2021 and 2024: Gains from Investment Securities surged 11429.59% in 2021, then tumbled 5538.0% in 2024.
- Biofrontera's Gains from Investment Securities stood at $11.1 million in 2021, then tumbled by 97.3% to $300000.0 in 2022, then slumped by 2285.33% to -$6.6 million in 2023, then soared by 94.65% to -$351000.0 in 2024, then plunged by 37.32% to -$482000.0 in 2025.
- Business Quant data shows BFRI's Gains from Investment Securities at -$482000.0 in Q4 2025, $285000.0 in Q3 2025, and -$153000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Biofrontera | 19.06 Mn | 14.35 Mn | 9.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44,000.00 |
| Jun 30, 2026 | -44,000.00 |
| Dec 31, 2025 | -482,000.00 |
| Dec 31, 2025 | -482,000.00 |
| Sep 30, 2025 | 285,000.00 |
| Sep 30, 2025 | 285,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -548,000.00 |
| Mar 31, 2025 | -548,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Dec 31, 2024 | -351,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | -5.44 Mn |
| Jun 30, 2024 | -5.44 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Dec 31, 2023 | -6.56 Mn |
| Dec 31, 2023 | -6.56 Mn |